Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 6 years
- Director since
- 2023
6 years of board service in total across 2 boards, counting each seat separately. Longest: Kiora Pharmaceuticals Inc., 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Kiora Pharmaceuticals Inc. June 4, 202593.5%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 8, 2026 | Contineum Therapeutics Inc. | Option exercise | +2,500 | $1.01 | $2,525 |
| Sep 8, 2026 | Contineum Therapeutics Inc. | Open-market sale | −2,500 | $16.46 | $41,150 |
| Aug 3, 2026 | Contineum Therapeutics Inc. | Option exercise | +2,500 | $1.01 | $2,525 |
| Aug 3, 2026 | Contineum Therapeutics Inc. | Open-market sale | −2,500 | $16.01 | $40,025 |
| Jul 8, 2026 | Contineum Therapeutics Inc. | Option exercise | +2,500 | $1.01 | $2,525 |
| Jul 8, 2026 | Contineum Therapeutics Inc. | Open-market sale | −2,500 | $16.00 | $40,000 |
| Jun 30, 2026 | Contineum Therapeutics Inc. | Option exercise | +7,500 | $1.01 | $7,575 |
| Jun 30, 2026 | Contineum Therapeutics Inc. | Option exercise | +2,500 | $1.26 | $3,150 |
| Jun 30, 2026 | Contineum Therapeutics Inc. | Open-market sale | −10,000 | $16.01 | $160,100 |
| Feb 25, 2026 | Contineum Therapeutics Inc. | Option exercise | +2,700 | $1.26 | $3,402 |
| Feb 25, 2026 | Contineum Therapeutics Inc. | Open-market sale | −2,700 | $16.02 | $43,254 |
| Feb 24, 2026 | Contineum Therapeutics Inc. | Option exercise | +4,400 | $1.26 | $5,544 |
| Feb 24, 2026 | Contineum Therapeutics Inc. | Open-market sale | −4,400 | $16.02 | $70,488 |
| Feb 11, 2026 | Contineum Therapeutics Inc. | Option exercise | +400 | $1.26 | $504 |
| Feb 11, 2026 | Contineum Therapeutics Inc. | Open-market sale | −400 | $16.00 | $6,400 |
Questions about Carmine N. Stengone
What boards is Carmine N. Stengone on?
Carmine N. Stengone sits on the boards of Contineum Therapeutics Inc. and Kiora Pharmaceuticals Inc.
What company is Carmine N. Stengone the CEO of?
Carmine N. Stengone has been CEO and President of Contineum Therapeutics Inc. since April 2024.
How long has Carmine N. Stengone served on boards?
Our records show at least 6 years of board service across 2 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.